Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma

Overview of attention for article published in Journal of Clinical Oncology, July 2009

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

patent: 34 patents

wikipedia: 4 Wikipedia pages

Readers on

mendeley: 73 Mendeley

So far, Altmetric has seen 34 patents that reference this research output.

Combination therapies with anti CD40 antibodies

Grant US-12570753-B2

United States of America

10 Mar 2026

ANTIBODY MOLECULES TO PD-1 AND USES THEREOF

Application EP-4424322-A2

European Patent Office

04 Sep 2024

COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1

Application EP-4378957-A2

European Patent Office

05 Jun 2024

ANTIBODY MOLECULES TO PD-L1 AND USES THEREOF

Application EP-4245376-A2

European Patent Office

20 Sep 2023

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 30 additional patents.